Alejandra Carvajal Sells 5,598 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Stock

by · The Cerbat Gem

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) SVP Alejandra Carvajal sold 5,598 shares of Mersana Therapeutics stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $1.96, for a total value of $10,972.08. Following the transaction, the senior vice president now directly owns 63,716 shares of the company’s stock, valued at approximately $124,883.36. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Mersana Therapeutics Stock Up 1.5 %

Shares of NASDAQ:MRSN opened at $1.99 on Wednesday. The company has a quick ratio of 2.72, a current ratio of 2.72 and a debt-to-equity ratio of 2.02. Mersana Therapeutics, Inc. has a 52-week low of $1.07 and a 52-week high of $6.28. The stock’s fifty day simple moving average is $1.68 and its 200-day simple moving average is $2.37. The company has a market capitalization of $243.50 million, a P/E ratio of -1.75 and a beta of 1.49.

Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). Mersana Therapeutics had a negative net margin of 349.98% and a negative return on equity of 333.91%. The company had revenue of $2.30 million during the quarter, compared to analysts’ expectations of $8.72 million. During the same quarter in the prior year, the company earned ($0.47) earnings per share. The firm’s revenue was down 78.3% compared to the same quarter last year. As a group, equities research analysts forecast that Mersana Therapeutics, Inc. will post -0.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Mersana Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Algert Global LLC purchased a new position in Mersana Therapeutics during the second quarter worth about $90,000. Susquehanna Fundamental Investments LLC lifted its position in Mersana Therapeutics by 31.9% during the second quarter. Susquehanna Fundamental Investments LLC now owns 308,691 shares of the company’s stock worth $620,000 after buying an additional 74,575 shares during the period. Squarepoint Ops LLC purchased a new position in Mersana Therapeutics during the second quarter worth about $508,000. Marshall Wace LLP lifted its position in Mersana Therapeutics by 358.0% during the second quarter. Marshall Wace LLP now owns 176,029 shares of the company’s stock worth $354,000 after buying an additional 137,596 shares during the period. Finally, XTX Topco Ltd lifted its position in Mersana Therapeutics by 262.1% during the second quarter. XTX Topco Ltd now owns 121,432 shares of the company’s stock worth $244,000 after buying an additional 87,893 shares during the period. 93.92% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Robert W. Baird reduced their price objective on Mersana Therapeutics from $4.00 to $3.00 and set a “neutral” rating for the company in a report on Wednesday, August 14th. Lifesci Capital upgraded Mersana Therapeutics to a “strong-buy” rating in a research report on Monday, July 29th. Finally, Citigroup reduced their price objective on Mersana Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Tuesday, August 27th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Mersana Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $6.00.

Read Our Latest Report on MRSN

Mersana Therapeutics Company Profile

(Get Free Report)

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.

Further Reading